236406-39-6

Basic information

• Product Name: 2,8-DIAZA-SPIRO[4.5]DECANE-8-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 2,8-Diazaspiro[4.5]decane-8-carboxylicacid, 1,1-diMethylethyl ester hydrochloride;2,8-Diazaspiro[4.5]decane-8-carboxylic acid tert-butyl ester hydrochloride;8-N-Boc-2,8-diaza-spiro[4.5]decane;tert-Butyl 3,8-diazaspiro[4.5]decane-8-carboxylate;TERT-BUTYL 2,8-DIAZASPIRO[4.5]DECANE-8-CARBOXYLATE;D67158;2,8-Diazaspiro[4.5]decane-8-carboxylic acid, 1,1-dimethylethyl ester;8-Boc-2,8-diaza-spiro[4.5...
• CAS NO: 236406-39-6
• Molecular Formula: C₁₃H₂₄N₂O₂
• Molecular Weight: 240.35
• Mol File: 236406-39-6.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 337.028 °C at 760 mmHg
• Flash Point: 157.629 °C
• Appearance: /
• Density: 1.073 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.515
• Storage Temp.: 2-8°C(protect from light)
• PKA: 11.04±0.20(Predicted)
• CAS DataBase Reference: 2,8-DIAZA-SPIRO[4.5]DECANE-8-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 2,8-DIAZA-SPIRO[4.5]DECANE-8-CARBOXYLIC ACID TERT-BUTYL ESTER(236406-39-6)
• EPA Substance Registry System: 2,8-DIAZA-SPIRO[4.5]DECANE-8-CARBOXYLIC ACID TERT-BUTYL ESTER(236406-39-6)

Safety Data

• Statements: 36/37/38
• Safety Statements: 26-36
• Hazardous Substances Data: 236406-39-6(Hazardous Substances Data)

Usage

Description

2,8-DIAZA-SPIRO[4.5]DECANE-8-CARBOXYLIC ACID TERT-BUTYL ESTER, also known as tert-Butyl 2,8-Diazaspiro[4.5]decane-8-carboxylate, is a white solid with unique chemical properties. It is a synthetic compound that has been found to have potential applications in various fields due to its specific structural characteristics.

Uses

Used in Pharmaceutical Industry:
2,8-DIAZA-SPIRO[4.5]DECANE-8-CARBOXYLIC ACID TERT-BUTYL ESTER is used as a key intermediate compound for the preparation of substituted aminoquinolones. These aminoquinolones act as DGKα inhibitors, which play a crucial role in immune activation. By targeting DGKα, these inhibitors can potentially modulate immune responses and be utilized in the development of therapeutic strategies for various immune-related disorders.

InChI:InChI=1/C13H24N2O2/c1-12(2,3)17-11(16)15-8-5-13(6-9-15)4-7-14-10-13/h14H,4-10H2,1-3H3

Upstream product

• 236406-37-4 tert-butyl 4-(hydroxymethyl)-4-(prop-2-en-1-yl)piperidine-1-carboxylate 
• 203662-20-8 8-t-butoxycarbonyl-3-hydroxy-2-oxa-8-azaspiro[4.5]decane 
• 1221818-05-8 tert-butyl 2-benzyl-1-oxo-2,8-diazaspiro[4.5]decane-8-carboxylate 
• 1228603-43-7 4-(2-oxoethyl)-piperidine-1,4-dicarboxylic acid 1-tert-butyl ester 4-ethyl ester 
• 146603-99-8 1-(1,1-dimethylethyl) 4-ethyl 4-(2-propenyl)-1,4-piperidinedicarboxylate 
• 142851-03-4 1-tert-butyl 4-ethyl piperidine-1,4-dicarboxylate 
• 236406-40-9 tert-butyl 2-benzyl-2,8-diazaspiro[4.5]decane-8-carboxylate 
• 236406-38-5 1,1-dimethylethyl 4-(2-hydroxyethyl)-4-(hydroxymethyl)-1-piperidinecarboxylate 

Downstream Products

• 236406-40-9 tert-butyl 2-benzyl-2,8-diazaspiro[4.5]decane-8-carboxylate 

Relevant articles and documents

Synthesis method of 2, 8-diazaspiro [4.5] decane-8-tert-butyl formate

The invention discloses a synthesis method of 2, 8-diazaspiro [4.5] decane-8-tert-butyl formate. The synthesis method comprises the following steps: 1, in a first reaction solvent, reacting a compound 1 with 1-bromo-2-chloroethane under the action of alkali to obtain a compound 2; 2, in a second reaction solvent, reducing the compound 2 by a reducing agent and then performing a cyclization reaction automatically, and obtaining a compound 3. The method has the advantages of easily available raw materials, convenience in operation, short route, high total yield, suitability for industrial production and the like, and mainly solves the technical problem that no suitable industrial synthesis method exists at present.

2-[BIS(4-FLUOROPHENYL)METHYL]-2,7-DIAZASPIRO[4.5]DECAN-10-ONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HUMAN DOPAMINE-ACTIVE-TRANSPORTER (DAT) PROTEIN FOR THE TREATMENT OF E.G. ATTENTION DEFICIT DISORDER (ADD)

The present invention provides compounds of formula (I) and in particular 2-[bis(4-fluorophenyl)methyl]-2,7- diazaspiro[4.5]decan-10-one derivatives and related compounds as inhibitors of human dopamine-active-transporter (DAT) protein for the treatment of sexual dysfunction, affective disorders, anxiety, depression, chronic fatigue, Tourette syndrome, Angelman syndrome, attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), obesity, pain, obsessive-compulsive disorder, movement disorders, CNS disorders, sleep disorders, narcolepsy, conduct disorder, substance abuse (including smoking cessation), eating disorders, and impulse control disorders.

Rifamycin derivatives

Novel rifamycin derivatives of formula I (both hydroquinone and corresponding quinone (C1-C4) forms): or their salts, hydrates or prodrugs thereof, wherein: a preferred R comprises hydrogen, acetyl; L is a linker, a preferred linker group elements selected from any combination of 1 to 5 groups shown FIG. 1, provided L is not wherein R1 is H, methyl or alkyl. The inventive compounds exhibit valuable antibiotic properties. Formulations having these compounds can be used in the control or prevention of infectious diseases in mammals, both humans and non-humans. In particular, the compounds exhibit a pronounced antibacterial activity, even against multiresistant strains of microbes.